The European Union's Important Projects of Common European Interest (IPCEIs) have emerged as essential tools for funding research, development, and infrastructure projects within the EU while ensuring compliance with competition regulations. Recently, the EU Commission approved two new IPCEIs, namely HY2Move and Med4Cure. HY2Move is dedicated to hydrogen and mobility, marking the fourth initiative in the hydrogen series. On the other hand, Med4Cure is the first IPCEI focused on health, aimed at supporting research, innovation, and the initial industrial deployment of healthcare products. These initiatives signify a significant step towards fostering innovation and technological advancement in critical areas such as hydrogen, mobility, and healthcare within the European Union. The approval of these new IPCEIs highlights the EU's commitment to driving progress and growth in key sectors while adhering to competition rules. The introduction of HY2Move and Med4Cure showcases the EU's dedication to supporting cutting-edge research, innovation, and the transition towards more sustainable and efficient solutions in the fields of hydrogen, mobility, and healthcare.